LT3580220T - Aminotriazolopiridinai, kaip kinazės inhibitoriai - Google Patents

Aminotriazolopiridinai, kaip kinazės inhibitoriai

Info

Publication number
LT3580220T
LT3580220T LTEPPCT/US2018/017755T LT18017755T LT3580220T LT 3580220 T LT3580220 T LT 3580220T LT 18017755 T LT18017755 T LT 18017755T LT 3580220 T LT3580220 T LT 3580220T
Authority
LT
Lithuania
Prior art keywords
aminotriazolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
LTEPPCT/US2018/017755T
Other languages
English (en)
Lithuanian (lt)
Inventor
Junqing Guo
Amy Hart
John Macor
Michael Mertzman
William Pitts
Steven Spergel
Scott Watterson
Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
Jie Chen
Carolyn Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3580220T publication Critical patent/LT3580220T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEPPCT/US2018/017755T 2017-02-13 2018-02-12 Aminotriazolopiridinai, kaip kinazės inhibitoriai LT3580220T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
LT3580220T true LT3580220T (lt) 2021-12-27

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/017755T LT3580220T (lt) 2017-02-13 2018-02-12 Aminotriazolopiridinai, kaip kinazės inhibitoriai

Country Status (25)

Country Link
US (3) US10913738B2 (OSRAM)
EP (1) EP3580220B1 (OSRAM)
JP (1) JP7097373B2 (OSRAM)
KR (1) KR102549952B1 (OSRAM)
CN (1) CN110520423B (OSRAM)
AU (1) AU2018217488B2 (OSRAM)
BR (1) BR112019016635A2 (OSRAM)
CA (1) CA3053484A1 (OSRAM)
CY (1) CY1124978T1 (OSRAM)
DK (1) DK3580220T3 (OSRAM)
EA (1) EA039808B1 (OSRAM)
ES (1) ES2902676T3 (OSRAM)
HR (1) HRP20212000T1 (OSRAM)
HU (1) HUE057801T2 (OSRAM)
IL (1) IL268614B (OSRAM)
LT (1) LT3580220T (OSRAM)
MA (1) MA47460A (OSRAM)
MX (1) MX378515B (OSRAM)
PL (1) PL3580220T3 (OSRAM)
PT (1) PT3580220T (OSRAM)
RS (1) RS62801B1 (OSRAM)
SG (1) SG11201907335UA (OSRAM)
SI (1) SI3580220T1 (OSRAM)
SM (1) SMT202200001T1 (OSRAM)
WO (1) WO2018148626A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2019089442A1 (en) * 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
MX2020007531A (es) 2018-01-26 2020-09-09 Bristol Myers Squibb Co Aminopirrolotriazinas como inhibidores de cinasa.
SG11202100130QA (en) 2018-07-09 2021-02-25 Lieber Institute Inc Pyridine carboxamide compounds for inhibiting nav1.8
KR102840599B1 (ko) * 2018-07-09 2025-07-29 리버 인스티튜트, 아이엔씨 Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물
WO2020056072A1 (en) 2018-09-13 2020-03-19 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
US12084426B2 (en) * 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
SG11202108064XA (en) * 2019-01-25 2021-08-30 Beijing Scitech Mq Pharmaceuticals Ltd Acylamino bridged heterocyclic compound, and composition and application thereof
EP3943488A4 (en) * 2019-03-22 2022-09-07 Genfleet Therapeutics (Shanghai) Inc. SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND METHOD FOR PREPARATION AND PHARMACEUTICAL USE
MX2022003769A (es) 2019-10-03 2022-04-20 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas.
AU2021219832B9 (en) * 2020-02-13 2024-02-15 Genfleet Therapeutics (Shanghai) Inc. Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
WO2023018643A1 (en) 2021-08-10 2023-02-16 Abbvie Inc. Nicotinamide ripk1 inhibitors
TW202345852A (zh) 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
AR133939A1 (es) * 2023-09-27 2025-11-19 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de cinasa
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004702A1 (en) * 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
US8865699B2 (en) 2007-11-27 2014-10-21 Cellzome Ltd. Amino triazoles as PI3K inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8598163B2 (en) 2009-02-04 2013-12-03 Vitae Pharmaceuticals, Inc. Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
CN105246891A (zh) 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
CN106573006A (zh) * 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
EP3372604B1 (en) * 2015-11-05 2021-12-01 Sumitomo Chemical Company, Limited Condensed heterocyclic compound
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
EP3575298B1 (en) 2017-01-24 2022-03-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
EP3580220B1 (en) * 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2019089442A1 (en) 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
MX2020007531A (es) 2018-01-26 2020-09-09 Bristol Myers Squibb Co Aminopirrolotriazinas como inhibidores de cinasa.
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
SI3580220T1 (sl) 2022-01-31
RS62801B1 (sr) 2022-02-28
WO2018148626A1 (en) 2018-08-16
IL268614B (en) 2021-12-01
EP3580220A1 (en) 2019-12-18
IL268614A (en) 2019-10-31
SG11201907335UA (en) 2019-09-27
CN110520423A (zh) 2019-11-29
CY1124978T1 (el) 2023-01-05
EA039808B1 (ru) 2022-03-16
HRP20212000T1 (hr) 2022-04-01
AU2018217488B2 (en) 2021-09-23
CA3053484A1 (en) 2018-08-16
MA47460A (fr) 2019-12-18
PL3580220T3 (pl) 2022-02-07
JP7097373B2 (ja) 2022-07-07
EP3580220B1 (en) 2021-11-17
KR102549952B1 (ko) 2023-06-29
AU2018217488A1 (en) 2019-10-03
CN110520423B (zh) 2022-08-23
US20250074909A1 (en) 2025-03-06
KR20190117006A (ko) 2019-10-15
EA201991915A1 (ru) 2019-12-30
ES2902676T3 (es) 2022-03-29
PT3580220T (pt) 2022-01-03
US10913738B2 (en) 2021-02-09
US12157733B2 (en) 2024-12-03
MX378515B (es) 2025-03-11
DK3580220T3 (da) 2022-01-10
US20220315580A1 (en) 2022-10-06
HUE057801T2 (hu) 2022-06-28
SMT202200001T1 (it) 2022-03-21
BR112019016635A2 (pt) 2020-04-07
US20190389859A1 (en) 2019-12-26
MX2019009555A (es) 2019-10-02
JP2020507582A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
LT3580220T (lt) Aminotriazolopiridinai, kaip kinazės inhibitoriai
IL269196A (en) Novel inhibitors
DK3303334T3 (da) Tyrosinkinasehæmmere
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
IL261904A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MA42242A (fr) Inhibiteurs de la tyrosine kinase
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
BR112017025986A2 (pt) inibidores de tirosina quinase de bruton.
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
HUE050842T2 (hu) Janus-kináz inhibitor
DK3571192T3 (da) Jak1-selektive inhibitorer
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
LT3609898T (lt) Junginiai, naudingi kaip ret inhibitoriai
SI3145929T1 (sl) 5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze
DK3290418T3 (da) Janus Kinase (JAK)-hæmmere
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3592745T3 (da) Pyrimidopyrimidinoner anvendelige som Wee-1 kinaseinhibitorer
LT3386991T (lt) Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
EP3713931C0 (en) 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE
DK3630744T3 (da) Pyrazol-magl-inhibitorer
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
EP3600301A4 (en) KDM4 INHIBITORS
MA44607A (fr) Inhibiteurs de kinase